4
Changes in Ownership
10x Genomics, Inc. Filed Acc 0001209191-20-057069
Chief Executive Officer sold 10,000 shares at an average $136.57 ($1,365,702)
- Chief Executive Officer acquired 10,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Saxonov Serge · Chief Executive Officer
Table I: Non-derivative
11 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-11-02 | Exercise or conversion : show line 1 in the form | +6,250 | $1.20 | $7,500 | 973,431 | D |
| 2020-11-02 | Exercise or conversion : show line 2 in the form | +826 | $5.04 | $4,163 | 974,257 | D |
| 2020-11-02 | Sale : show line 3 in the form | −1,624 | $135.45 | $219,978 | 972,633 | D |
| 2020-11-02 | Sale : show line 4 in the form | −4,052 | $136.13 | $551,587 | 968,581 | D |
| 2020-11-02 | Sale : show line 5 in the form | −500 | $137.10 | $68,552 | 968,081 | D |
| 2020-11-02 | Sale : show line 6 in the form | −900 | $138.54 | $124,686 | 967,181 | D |
| 2020-11-03 | Exercise or conversion : show line 7 in the form | +2,924 | $5.04 | $14,737 | 970,105 | D |
| 2020-11-03 | Sale : show line 8 in the form | −200 | $135.54 | $27,107 | 969,905 | D |
| Open-market sales · 10,000 sh · avg $136.57 · $1,365,702 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2020-11-02 | Exercise or conversion : show line 12 in the form Stock Option (right to buy) | −6,250 | $1.20 | 2027-10-18 | 6,250 | 116,110 | D |
| 2020-11-02 | Exercise or conversion : show line 13 in the form Stock Option (right to buy) | −826 | $5.04 | 2028-11-02 | 826 | 131,189 | D |
| 2020-11-03 | Exercise or conversion : show line 14 in the form Stock Option (right to buy) | −2,924 | $5.04 | 2028-11-02 | 2,924 | 128,265 | D |
Loading xslF345X03/doc4.xml…